From the Division of Blood and Marrow Transplantation, Department of Pediatrics, and Division of Hematological Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine; Duke Cancer Institute; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina; and Data, Informatics and Statistics Core, Palliative Care Research Cooperative, Durham, North Carolina; and Flatiron Health, New York, New York.
J Natl Compr Canc Netw. 2018 Mar;16(3):267-273. doi: 10.6004/jnccn.2017.7048.
NCCN defines distress as a multifactorial, unpleasant emotional experience of a psychological nature that may interfere with patients' ability to cope with cancer symptoms and treatment. Patients with myelodysplastic syndromes (MDS) are at risk for distress due to the largely incurable nature of this hematopoietic malignancy and its symptom burden, yet associations with clinical outcomes are unknown. We retrospectively reviewed patient-reported distress data from adult ambulatory patients with MDS visiting a single, tertiary care medical center from July 2013 to September 2015. Demographic, diagnostic, treatment, and comorbidity information were abstracted from records along with NCCN Distress Thermometer (DT) and Problem List (PL) scores. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazards regression. We abstracted 376 DT scores (median, 1; range, 0-10) from 606 visits and 110 patients (median, 2 DT scores/patient; range, 1-16). NCCN Guidelines suggest that patients with DT scores ≥4 should be evaluated for referral to specialty services to address unmet needs. A total of 54 patients (49%) had at least 1 DT score ≥4 and 20 (18%) had 2 or more DT scores ≥4; 98 patients (89.1%) reported 1,379 problems during 23,613 person-days of follow-up (median, 4 problems/patient/visit; range, 1-23). The 5 most frequently reported problems were fatigue (181 times; 78 patients), pain (95 times; 46 patients), worry (80 times; 45 patients), sleep (78 times; 41 patients), and tingling hands/feet (68 times; 33 patients). After adjustment for risk stratification at diagnosis, a single point increase on the DT was associated with an increased risk of death (hazard ratio, 1.18; 95% CI, 1.01-1.36). Patients with MDS experience a high burden of distress, and patient-reported distress is associated with clinical outcomes. Distress should be further studied as a prognostic variable and a marker of unmet needs in MDS.
NCCN 将痛苦定义为一种多因素的、不愉快的心理体验,可能会干扰患者应对癌症症状和治疗的能力。患有骨髓增生异常综合征 (MDS) 的患者由于这种血液恶性肿瘤的大部分无法治愈的性质及其症状负担而面临痛苦的风险,但与临床结果的关联尚不清楚。我们回顾性地审查了 2013 年 7 月至 2015 年 9 月期间在一家三级护理医疗中心就诊的成年门诊 MDS 患者的患者报告的痛苦数据。从记录中提取人口统计学、诊断、治疗和合并症信息,以及 NCCN 痛苦温度计 (DT) 和问题清单 (PL) 评分。使用 Kaplan-Meier 方法和 Cox 比例风险回归分析生存情况。我们从 606 次就诊和 110 名患者中提取了 376 个 DT 评分(中位数 1;范围 0-10)。NCCN 指南建议,DT 评分≥4 的患者应接受专科服务评估,以满足未满足的需求。共有 54 名患者(49%)至少有 1 个 DT 评分≥4,20 名患者(18%)有 2 个或更多 DT 评分≥4;98 名患者(89.1%)在 23613 人天的随访中报告了 1379 个问题(中位数为每个患者/就诊 4 个问题;范围 1-23)。报告最多的 5 个问题是疲劳(181 次;78 名患者)、疼痛(95 次;46 名患者)、担忧(80 次;45 名患者)、睡眠(78 次;41 名患者)和手脚刺痛(68 次;33 名患者)。在调整诊断时的风险分层后,DT 增加一个点与死亡风险增加相关(风险比,1.18;95%CI,1.01-1.36)。MDS 患者经历着沉重的痛苦负担,患者报告的痛苦与临床结果相关。痛苦应作为 MDS 的预后变量和未满足需求的标志物进一步研究。